Friday October 17th, 2008

8.30 am

Registration of participants

9.00 am

Grand opening
Daniel Louvard (Institut Curie, Paris, France)

Introduction
Guido Kroemer (Institut Gustave Roussy, Villejuif, France)

9.30 am – 10.30 am

Session 1: Immunogenic anti-cancer chemotherapy as an emerging concept

9.30 : Mark J. Smyth (Peter MacCallum Cancer Centre, Melbourne, Australia): Anti-cancer immunosurveillance and anti-cancer immune responses
10.00: Robert Schreiber (Washington University School of Medicine, St. Louis, MO, USA): Immunoediting and cancer dormancy

10.30 – 11.00 am

Coffee- break

11.00 am – 12.30 pm

Session 2: Death and danger signals

11.00: Guido Kroemer (INSERM, Institut Gustave Roussy, Univ Paris-Sud, Villejuif, France): Immunogenic cancer cell death: the goal of immunochemotherapy
11.30: Madhav V. Dhodapkar (Rockefeller University, New York, USA): Heat shock proteins at the surface of dying tumor cells 12.00: Scott W. Lowe (Cold Spring Harbor Laboratory, NY, USA): Immunoresponse against therapy-induced senescence of cancer cells
12.00 Immunoresponse against therapy-induced senescence of cancer cells
Scott W. Lowe (Cold Spring Harbor Laboratory, NY, USA)

12.30 pm – 2.00 pm

Lunch

2.00 pm – 3.30 pm

Session 2: Death and danger signals (continuation)

2.00: John Savill (University of Edinburgh, Scotland, UK): Recognition of dying cells by the innate immune system
2.30: Peter Vandenabeele (University of Ghent, Belgium): Apoptosis, necrosis and autophagy elicit distinct mechanisms of corpse removal
3.00: Matthew L. Albert (Pasteur Institute, Paris, France): Molecular determinants of immunogenic cell death

3.30 pm – 4.30 pm

Session 3: The perception of danger signals

3.30: Gabriel Nunes (University of Michigan, Ann Arbor, MI, USA):  Pyroptosis and the inflammasome: a new type of response to danger
4.00: Tadatsugu Taniguchi  (University of Tokyo, Japan): Cytoplasmic receptors for the perception of danger

4.30 pm – 5.00 pm

Coffee-break

5.00 pm – 6.30 pm

Session 3: The perception of danger signals (continuation)

4.30: Ruslan Medzhitov  (Yale University, USA): Toll-like receptors in oncogenesis
5.00 Toll-like receptors in oncogenesis
Ruslan Medzhitov (Yale University, USA)
5.30 Danger signaling via toll-like receptors
Jules Hoffmann (IGBMC, Strasbourg, France)
6.00 How dendritic cells sense immunogenic cell death
Laurence Zitvogel (Institut Gustave Roussy, INSERM, Univ. Paris-Sud, Villejuif, France)

7.00 pm – 11.30 pm

Gala dinner - Cruise on the Seine river

Saturday October 18th, 2008

8.00 am

Registration of participants

8.30 am – 10.30 am

Session 4: Dendritic cells: decoding the trigger

8.30: Sebastian Amigorena  (INSERM, Institut Curie, Paris, France): Antigen presentation by dendritic cells: an update
9.00: Jacques Banchereau (Baylor Institute, Dallas, TX, USA): Anti-cancer vaccination strategies based on the use of dendritic cells
9.30: Miriam Merad (Memorial Sloan Kettering Institute, New York, USA): Tolerogenic versus immunogenic signals emanating from dendritic cells
10.00: Frederic Geissmann (INSERM, Necker Hospital, Paris, France): Dendritic cells and their precursors

10.30 – 11.00 am

Coffee-break

11.00 – 1.00 pm

Session 5 : Clinical studies and beyond

11.00 : Malcom Adams (Cancer Services, Velindre NHS Trust, Cardiff, UK)
11.30: Gerold Schuler (University of Erlangen, Germany): A meta-analysis of dendritic cell vaccination trials
12.00: Anna Karolina Palucka  (Baylor Institute, Dallas, TX, USA): Dentritic cell vaccination trials at Baylor Institute
12.30: Xuetao Cao (Second Military Medical University, Shanghai, China): A successful chemoimmunotherapy protocol for the treatment of hepatocellular carcinoma

1.00 – 2.00 pm

Lunch

2.00 pm – 4.00 pm

Session 5 : Clinical studies and beyond (continuation)

2.00: Ira Mellman (Genentech, San Francisco, CA, USA)
2.30: James Allison (Memorial Sloan-Kettering Cancer Center, NY, USA)
3.00: Bruno Quesnel (INSERM, Lille, France)
3.30: Ron Levy (Division of Oncology, Stanford, CA, USA)

4.00 – 4.30 am

Coffee-break

4.30 – 6.30 pm

Session 5 : Clinical studies and beyond (continuation)

4.30: Jean Yves Bonnefoy (Transgene)
5.00: Yannis Morel (Innate Pharma)
5.30: Richard Piani (Hemispherx) : Clinical development of TLR3 agonists
6.00: Jean Edouard Gairin (Pierre Fabre Oncologie):

6.30 – 7.00 pm

Concluding remarks - discussion

End of the Conference